Superparamagnetic iron oxide contrast agents: Physicochemical characteristics and applications in MR imaging

European Radiology

Volumn 11, Issue 11, 2001, Pages 2319-2331

  Wang, Y X J ^a   Hussain, S M ^a   Krestin, G P ^a  

^a ERASMUS MEDICAL CENTER   (Netherlands)

Author keywords

Contrast agent; Iron oxide; MR imaging; Superparamagnetism

Indexed keywords

AMI 277; CONTRAST MEDIUM; FERRISTENE; FERUMOXSIL; LUMIREN; NANOPARTICLE; OMP; REVOVIST; SUPERPARAMAGNETIC IRON OXIDE; ULTRASMALL SUPERPARAMAGNETIC IRON OXIDE; UNCLASSIFIED DRUG;

ANGIOGRAPHY; ARTICLE; BIODEGRADATION; BONE MARROW; CLINICAL RESEARCH; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; CRYSTAL STRUCTURE; DIAGNOSTIC IMAGING; DRUG FORMULATION; DRUG HALF LIFE; HUMAN; INTESTINE; LIVER; LYMPH NODE; NUCLEAR MAGNETIC RESONANCE IMAGING; PARTICLE SIZE; PERFUSION; PHARMACOKINETICS; PHASE 3 CLINICAL TRIAL; PHYSICAL CHEMISTRY; PRIORITY JOURNAL; SOLUBILITY; SPLEEN;

CONTRAST MEDIA; FERRIC COMPOUNDS; MAGNETIC RESONANCE IMAGING; MAGNETICS;

EID: 0034753215     PISSN: 09387994     EISSN: None     Source Type: Journal    
DOI: 10.1007/s003300100908     Document Type: Article

References (90)

1. Ferrimagnetic susceptibility contrast agents
2. Hepatic MRI with SPIO: Detection and characterization of focal liver lesions
3. Comparative efficacy of and sequence choice for two oral contrast agents used during MR imaging
4. Magnetic resonance imaging of esophageal squamous cell carcinoma using magnetite particles coated with anti-epidermal growth factor receptor antibody
5. Targeting of ultrasmall superparamagnetic iron oxide (USPIO) particles to tumor cells in vivo by using transferrin receptor pathways
6. Superparamagnetically labelled neutrophils as potential abscess-specific contrast agent for MRI
7. Hysteresis loops of mixture of ferromagnetic micropowders
8. Superparamagnetism
9. Physical and chemical properties of superparamagnetic iron oxide MR contrast agents: Ferumoxides, ferumoxtran, ferumoxsil
10. Ultrasmall superparamagnetic iron oxide: Characterization of a new class of contrast agents for MR imaging
11. Differences in predominant enhancement mechanisms of superparamagnetic iron oxide and ultrasmall superparamagnetic iron oxide for contrast-enhanced portal magnetic resonance angiography. Preliminary original investigation
12. Biologically degradable superparamagnetic materials for use in clinical applications
13. Synthesis of polysaccharide covered superparamagnetic oxide colloids
14. Antimyosin-labeled monocrystalline iron oxide allows detection of myocardial infarct: MR antibody imaging
15. Polyclonal human immunoglobulin G labeled with polymeric iron oxide: Antibody MR imaging
16. Development of superparamagnetic nanoparticles for MRI: Effect of particle size, charge and surface nature on biodistribution
17. Long-circulating iron oxides for MR imaging
18. Clinical results with Resovist: A phase 2 clinical trial
19. CBF and CBV measurements by USPIO bolus tracking: Reproducibility and comparison with Gd-based values
20. First clinical trial of a new superparamagnetic iron oxide for use as an oral gastrointestinal contrast agent in MR imaging
21. Experimental lymph node metastases: Enhanced detection with MR lymphography
22. Superparamagnetic iron oxide: Pharmacokinetics and toxicity
23. Phase I clinical evaluation of a new iron oxide MR contrast agent
24. NC100150-enhanced 3D-SPGR MR angiography of the common carotid artery in a pig vascular stenosis model. Quantification of stenosis and dose optimization
25. Ultrasmall superparamagnetic iron oxide to enhance MRA of the renal and coronary arteries: Studies in human patients
26. Use of an intravascular T1 contrast agent to improve MR cine myocardial-blood pool definition in man
27. MR contrast material for vascular enhancement: Value of superparamagnetic iron oxide
28. Initial clinical experience with dextran-coated superparamagnetic iron oxide for detection of lymph node metastases in patients with head and neck cancer
29. Imaging of nodal metastases in the head and neck
30. Dextran-coated superparamagnetic iron oxide MR contrast agent (Combidex) for imaging cervical lymph nodes: Optimal dose, time of imaging, and pulse sequence (abstract)
31. Value of blood pool contrast agents in magnetic resonance angiography of the pelvis and lower extremities
32. Preliminary experience of cardiac perfusion with a novel intravascular contrast agent (SHU 555C) in humans
33. MRA with a new blood pool contrast agent: Phase I clinical trial
34. Contribution of Abdoscan in MRI cholangio-pancreatography and MRI urography (in French)
35. RES-specific imaging of the liver and spleen with iron oxide particles designed for blood pool MR-angiography
36. Abdominal MR: Liver and pancreas
37. Detection of hepatic metastases: Ferumoxides-enhanced MR imaging versus unenhanced MR imaging and CT during arterial portography
38. Hepatic MR imaging with ferumoxides: A multicenter clinical trial of the safety and efficacy in the detection of focal hepatic lesions
39. T1-weighted dynamic MRI with new superparamagnetic iron oxide particles (Resovist): Results of a phantom study as well as 25 patients (in German)
40. Contrast-enhanced 3D-MRA of the upper abdomen with a bolus-injectable SPIO (SHU 555A)
41. Enhancement of liver hemangiomas on T1-weighted MR SE images by superparamagnetic iron oxide particles
42. Differentiation of liver hemangiomas from metastases and hepatocellular carcinoma at MR imaging enhanced with blood-pool contrast agent Code-7227
43. Blood-pool MR contrast material for detection and characterization of focal hepatic lesions: Initial clinical experience with ultrasmall superparamagnetic iron oxide (AMI-227)
44. Acute liver rejection: Evaluation with cell-directed MR contrast agents in a rat transplantation model
45. Early detection of radiation-induced liver injury in rat by superparamagnetic iron oxide-enhanced MR imaging
46. MR imaging enhancement with superparamagnetic iron oxide in chronic liver disease: Influence of liver dysfunction and parenchymal pathology
47. Dose-dependency and rate of decay of efficacy of Resovist on MR images in a rat cirrhotic liver model
48. Contrast-enhanced MR imaging of diffuse and focal splenic disease with use of magnetic starch microspheres
49. Lymph node metastases: Safety and effectiveness of MR imaging with ultrasmall superparamagnetic iron oxide particles - Initial clinical experience
50. Characterization of reactive versus tumor-bearing lymph nodes with interstitial magnetic resonance lymphography in an animal model
51. Bone marrow: Ultrasmall superparamagnetic iron oxide for MR imaging
52. Mechanisms of accumulation of small particles of iron oxide in experimentally induced osteosarcomas of rats: A correlation of magnetic resonance imaging and histology. Preliminary results
53. Evaluation of an ultrasmall superparamagnetic iron oxide in MRI in a bone tumor model in rabbits
54. Monitoring radiation-induced changes in bone marrow histopathology with ultra-small superparamagnetic iron oxide (USPIO)-enhanced MRI
55. Ferumoxides-enhanced quantitative magnetic resonance imaging of the normal and abnormal bone marrow: Preliminary assessment
56. In vivo macrophage activity imaging in the central nervous system detected by magnetic resonance
57. Study of relapsing remitting experimental allergic encephalomyelitis SJL mouse model using MION-46L enhanced in vivo MRI: Early histopathological correlation
58. MR imaging of intrarenal macrophage infiltration in an experimental model of nephrotic syndrome
59. MR imaging of atherosclerotic plaque with ultrasmall superparamagnetic iron oxide in hyperlipedemic rabbits
60. Determinants of in vivo MR imaging of slow axonal transport
61. MR imaging of neuronal transport in the guinea pig facial nerve: Initial findings
62. Safety and preliminary findings with the intravascular contrast agent NC100150 injection for MR coronary angiography
63. Pulmonary MR angiography with ultrasmall superparamagnetic iron oxide particles as a blood pool agent and a navigator echo for respiratory gating: Pilot study
64. Pulmonary hemorrhage: Imaging with a new magnetic resonance blood pool agent in conjunction with breathheld three-dimensional magnetic resonance angiography
65. Intestinal and peritoneal bleeding: Detection with an intravascular contrast agent and fast three-dimensional MR imaging - Preliminary experience from an experimental study
66. MRI in acute cerebral ischaemia: Perfusion imaging with superparamagnetic iron oxide in a rat model
67. Continuous assessment of relative cerebral blood volume in transient ischemia using steady state susceptibility-contrast MRI
68. Contribution of Sinerem used as blood-pool contrast agent: Detection of cerebral blood volume changes during apnea in the rabbit
69. High-resolution functional magnetic resonance imaging of the rat brain: Mapping changes in cerebral blood volume using iron oxide contrast media
70. Magnetic resonance imaging with superparamagnetic iron oxide particles for the detection of myocardial reperfusion
71. Superparamagnetic iron oxide particles and positive enhancement for myocardial perfusion studies assessed by sub-second T1-weighted MRI
72. NC100150 injection: A new intravascular MR contrast agent for morphological and functional assessment of the heart (abstract)
73. First-pass myocardial perfusion imaging and equilibrium signal changes using the intravascular contrast agent NC100150 injection
74. (19) First-pass evaluation of renal perfusion with TurboFLASH MR imaging and superparamagnetic iron oxide particles
75. USPIO-enhanced MR imaging of glycerol-induced acute renal failure in the rabbit
76. Use of T(2)-weighted susceptibility contrast MRI for mapping the blood volume in the glioma-bearing rat brain
77. NMR imaging of changes in vascular morphology due to tumor angiogenesis
78. Perfusion MR imaging with a superparamagnetic iron oxide using T2-weighted and susceptibility-sensitive echoplanar sequences: Evaluation of tumor vascularity in hepatocellular carcinoma
79. Antibody-magnetite nanoparticles: In vitro characterization of a potential tumor-specific contrast agent for magnetic resonance imaging
80. Development of a target-directed magnetic resonance contrast agent using monoclonal antibody-conjugated magnetic particles
81. MR of carcinoma-specific monoclonal antibody conjugated to monocrystalline iron oxide nanoparticles: The potential for noninvasive diagnosis
82. Monoclonal antibody-coated magnetic particles as contrast agents in magnetic resonance imaging of tumors
83. Pancreatic receptors: Initial feasibility studies with a targeted contrast agent for MR imaging
84. MION-ASF: Biokinetics of an MR receptor agent
85. Use of an asialoglycoprotein receptor-targeted magnetic resonance contrast agent to study changes in receptor biology during liver regeneration and endotoxemia in rats
86. Magnetically labeled cells can be detected by MR imaging
87. Cellular uptake and trafficking of a prototypical magnetic iron oxide label in vitro
88. In vivo dynamic MRI tracking of rat T-cells labeled with superparamagnetic iron-oxide particles
89. Magnetic resonance imaging of abscesses using lipid-coated iron oxide particles
90. Dose and scanning delay using USPIO for central nervous system macrophage imaging